EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Rohit Loomba iD, Arun J Sanyal, Kris V Kowdley, Deepak L Bhatt, Naim Alkhouri iD, Juan P Frias iD, Pierre Bedossa, Stephen A Harrison, Donald Lazas, Robert Barish, Mildred D Gottwald, Shibao Feng und 5 weitere

New England Journal of Medicine · 14.09.2023 · 389 (11) · 998-1008

DOI: 10.1056/nejmoa2304286 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 14.09.2023. Verfasst von Rohit Loomba und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Diego, La Jolla (R…. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Fibrosis, Gastrointestinal Agents, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 541-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, 89bio.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsFibrosisGastrointestinal AgentsNon-alcoholic Fatty Liver DiseaseHumansBiopsyDouble-Blind MethodInjections, SubcutaneousTreatment Outcome

Substanzen

fibroblast growth factor 21Fibroblast Growth FactorsGastrointestinal Agents

Autor:innen und Institutionen

  • From the NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Diego, La Jolla (R.L.), Velocity Clinical Research, Los Angeles (J.P.F.), and 89bio, San…

ORCID-Profile: Rohit Loomba, Naim Alkhouri, Juan P Frias

Förderung

  • NIDDK NIH HHS
  • 89bio

Zitieren

APA

Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., Gottwald, M. D., Feng, S., Agollah, G. D., Hartsfield, C. L., Mansbach, H., Margalit, M., & Abdelmalek, M. F. (2023). Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. New England Journal of Medicine, 389(11), 998-1008. https://doi.org/10.1056/nejmoa2304286

Vancouver

Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. New England Journal of Medicine. 2023;389(11):998-1008. doi:10.1056/nejmoa2304286

BibTeX
@article{Loomba2023,
  author = {Loomba, Rohit and Sanyal, Arun J and Kowdley, Kris V and Bhatt, Deepak L and Alkhouri, Naim and Frias, Juan P and Bedossa, Pierre and Harrison, Stephen A and Lazas, Donald and Barish, Robert and Gottwald, Mildred D and Feng, Shibao and Agollah, Germaine D and Hartsfield, Cynthia L and Mansbach, Hank and Margalit, Maya and Abdelmalek, Manal F},
  title = {Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {11},
  pages = {998--1008},
  doi = {10.1056/nejmoa2304286}
}
Kostenlos starten →